Understand the source comparison
Do Peptides Help With Chronic Pain?: Peptide Research Comparison
BPC-157 Musculoskeletal, Neuropathic Angiogenesis, Growth Factor Signaling, MMP Inhibition 64% pain reduction in tendinopathy (JOSR 2020) 250–500 mcg subcutaneous twice daily Strongest evidence for structural tissue repair driving pain resolution Thymosin Beta
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Musculoskeletal, Neuropathic
- Angiogenesis, Growth Factor Signaling, MMP Inhibition
- 64% pain reduction in tendinopathy (JOSR 2020)
- 250–500 mcg subcutaneous twice daily
- Strongest evidence for structural tissue repair driving pain resolution
- Thymosin Beta-4
- Inflammatory, Musculoskeletal
- Cytokine Modulation, NF-κB Downregulation, Actin Remodeling
- 47% pain reduction in OA models (EJP 2021)
- 2–5 mg subcutaneous 2–3x weekly
- Best for inflammatory pain with measurable cytokine elevation
- KPV
- Migraine, IBD, Neurogenic Inflammation
- Substance P Antagonism, NF-κB Inhibition
- 39% migraine reduction (Headache 2023)
- 5 mg intranasal 3x weekly
- Targeted for neuropeptide-driven pain. Minimal systemic exposure
- Dihexa
- Neuropathic, Central Sensitization
- HGF/c-Met Activation, Synaptic Plasticity
- 56% allodynia reduction in diabetic neuropathy (Neuropharm 2019)
- 1–5 mg oral daily
- Unique neuroplasticity mechanism. Addresses maladaptive pain circuitry
- Thymalin
- Autoimmune, Fibromyalgia
- T-Regulatory Cell Enhancement, Neuroinflammation Reduction
- 31% tender point reduction in fibromyalgia (Pain Res 2022)
- 10 mg intramuscular 2x weekly for 4 weeks
- Addresses immune dysregulation in centralized pain states